Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Repligen acquires BioLife Solutions in $1.5 billion deal to expand cell therapy business
00

Repligen acquires BioLife Solutions in $1.5 billion deal to expand cell therapy business

Jul 22, 2026

Repligen will acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal to expand its cell therapy business. The offer values BioLife at $31 per share, a 6.2% premium. The deal gives Repligen access to BioLife's cell preservation technology, used in ~90% of approved cell therapies, and is expected to generate at least $20 million in first-year savings amid a recovery in the bioprocessing sector.

Repligen-BioLife acquisition terms

  • ▪BioLife Solutions shareholders will receive $11.25 in cash and 0.1442 Repligen shares for each of their shares
  • ▪The offer values BioLife Solutions at $31 per share, representing a premium of about 6.2% to its last closing price
  • ▪The boards of both Repligen and BioLife Solutions have unanimously approved the deal, which is expected to close in the fourth quarter of 2026
  • ▪Repligen Corp will acquire BioLife Solutions in a cash-and-stock deal valued at approximately $1.5 billion

Cell therapy market expansion

  • ▪The acquisition is intended to expand Repligen's presence in the fast-growing cell therapy market
  • ▪BioLife Solutions' products are used in approximately 90% of commercially approved cell therapies
  • ▪The deal gives Repligen access to BioLife's cell preservation technology, cell-processing tools, and high-margin consumables business

Bioprocessing industry recovery

  • ▪The deal follows a recent $11.3 billion acquisition of Bio-Techne by Merck KGaA, underscoring growing interest in drug development tool companies
  • ▪The acquisition comes amid a signaled recovery in demand for bioprocessing products as biotech and pharmaceutical companies increase spending

Deal financial impact

  • ▪Shares of BioLife Solutions rose about 3% in premarket trading following the announcement
  • ▪The acquisition is expected to increase Repligen's earnings and generate at least $20 million in cost savings in the first year

BioLife strategic refocus

  • ▪The sale of its logistics unit allowed BioLife to focus more on products related to cell and gene therapy
  • ▪In October 2025, BioLife Solutions sold its evo cold-chain logistics unit for $25.5 million

1 source

Reuters
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business | Reuters
View source article

Story comments

Loading comments…

Topics

Drug Approval and Clinical TrialsDrug Policy, Pricing & ApprovalPharma